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Abstract
Hepatocellular carcinoma (HCC) typically develop in cirrhosis, a condition characterized by
Hedgehog (Hh) pathway activation and accumulation of Hh-responsive myofibroblasts (MF).
Although Hh signaling generally regulates stromal-epithelial interactions that support epithelial
viability, the role of Hh-dependent MF in hepatocarcinogenesis is unknown. Here we used human
HCC samples, a mouse HCC model, and hepatoma cell/MF co-cultures to examine the hypothesis
that Hh signaling modulates MF metabolism to generate fuels for neighboring malignant
hepatocytes. The results identify a novel paracrine mechanism whereby malignant hepatocytes
produce HH-ligands to stimulate glycolysis in neighboring MF, resulting in release of MF-derived
lactate that the malignant hepatocytes use as an energy source. This discovery reveals new
diagnostic and therapeutic targets that might be exploited to improve the outcomes of cirrhotic
patients with HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common deadly forms of cancer
worldwide (1). HCCs typically develop in cirrhotic livers (1). The latter compromises
recovery from extensive liver resection, and restricts chemotherapy options and efficacy.
Therefore, survival depends mainly upon detection of tumors that are small enough to be
safely ablated. Better screening and preventative strategies are needed, however, because the
number of HCCs that are already advanced at diagnosis is increasing, and the population at
risk for HCC is growing due to the rising incidence of cirrhosis (1). Improved understanding
of the early events in hepatocarcinogenesis would help to optimize prevention, early
diagnosis, and treatment of HCC.
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Evidence that HCC occur in 1-5% of cirrhotic patients annually suggests that the cirrhotic
microenvironment promotes the outgrowth of malignant hepatocytes (2). However, the
mechanisms involved remain obscure. One possibility is that that stromal-epithelial
interactions fuel HCC growth because deregulated, and excessively fibrogenic, repair of
liver injury causes cirrhosis itself (3). The major producers of fibrous matrix during liver
injury are myofibroblasts (MF), and cirrhotic livers harbor large numbers of these cells. The
role of MF in HCC pathogenesis/progression is unclear, however, despite evidence that MF-
derived factors mediate key aspects of the wound healing response including matrix
turnover, recruitment of inflammatory cells, vascular remodeling, and outgrowth of liver
epithelial progenitors (4). The pivotal importance of MF in cirrhosis pathogenesis justifies
evaluating their role in hepatocarcinogenesis.
A key regulator of MF is Hedgehog (Hh), a developmental morphogenic signaling pathway
(5). Hh pathway activity is barely detectable in healthy livers but becomes robust during all
types of liver injury. Injured liver epithelial cells are important drivers of this process
because injury stimulates the wounded epithelia to produce and release Sonic hedgehog
(Shh) and Indian Hedgehog (Ihh) ligands, as well as other soluble factors, that promote Hh
signaling in neighboring Hh-responsive stromal cells (6, 7). Like other Hh-responsive
stromal cells, MF express the Hh ligand transmembrane receptor, Patched (Ptc) (8).
Interaction of epithelia-derived HH-ligands with Ptc results in the activation of Smoothened,
the Hh signaling-competent co-receptor. This leads to accumulation and nuclear localization
of Glioma-family proteins (Gli1, Gli2, Gli3) which regulate the transcription of Hh-
responsive genes that control proliferation, viability, and differentiation of the stromal cells.
Exchange of paracrine signals between Hh-producing epithelia and Hh-responsive stroma
orchestrates organogenesis during development. Similar mechanisms are presumed to
modulate some types of carcinogenesis based on findings in mouse models of pancreatic and
prostate cancer (9, 10). Although increased Hh signaling has been documented in human
HCC (11), and liver MF are known to be a Hh-responsive cell type, the possibility that HCC
growth might be regulated by paracrine Hh signaling between MF and malignant
hepatocytes has not, to our knowledge, been examined.
Recently, we demonstrated that treating a mouse model of fibrosis-associated HCC with a
Hh signaling inhibitor caused advanced HCCs to regress (12). Tumor involution was
accompanied by MF loss and fibrosis improvement. This suggests that the anti-cancer
actions of the Smoothened antagonist may have resulted from deletion of Hh-responsive
MF, and justifies further work to identify how MF might support the growth of malignant
hepatocytes. Here we evaluate the hypothesis that Hh signaling modulates MF metabolism
to generate fuels for neighboring malignant hepatocytes. Given that HCCs, like many other
epithelial cancers, exhibit enhanced glycolysis (i.e., the Warburg effect) (13), we asked if
HCC glycolytic activity was influenced by Hh signaling in tumor-associated MF.
Materials and Methods
Human subjects
The Duke Department of Pathology computer database was searched for cases of HCC
arising in nonalcoholic fatty liver disease (NAFLD) patients from 2007 through 2011. Five
cases were identified from resections, hepatectomies, and explants. Random tissue blocks
containing both tumor and adjacent non-tumor were used.
Mice and cell culture
Ten Mdr2−/− mice (age 51-59 weeks) with advanced liver fibrosis and HCC were treated
with either Vehicle (DMSO, n=5) or 40mg/kg GDC-0449 (n=5) for 9 days as described (12).
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Liver MF (8B cells, M. Rojkind, George Washington University (14)) were cultured alone
(monoculture) or in a Transwell co-culture system with HepG2 cells (ATCC), Huh 7.5 cells
(C. Rice, Rockefeller University), or Panc 10.05 cells (Duke Cell Culture Facility). MF
monocultures were also treated with PBS-control or 1000 ng/ml recombinant Shh ligand +/−
DMSO-vehicle or 3μM GDC-0449, or conditioned medium from the other cells +/− IgG-
control or 10ug/ml 5E1-antibody for 24 hours. HepG2 and Huh7.5 cells were grown alone
or treated with lactate +/− FX11. See Supplemental Methods for details.
Statistical analyses
Mean data were compared using the Student’s t-test. Differences were considered significant
when p<0.05.
Results and Discussion
Malignant epithelia produce HH-ligands and stroma is enriched with Hh-responsive,
glycolytic MF in human HCC
To investigate Hh ligand expression and localization in HCC, we performed
immunohistochemistry for Sonic Hedgehog (SHH) ligand in archived paraffin-embedded
tissues from 5 patients with HCC and cirrhosis caused by nonalcoholic fatty liver disease
(NAFLD). All of the HCCs demonstrated increased expression of SHH relative to their
capsules and adjacent non-tumorous liver tissue (Figure 1A). Within tumor nodules,
malignant hepatocytes were a major source of SHH ligand. In contrast, nuclear staining for
the Hh-regulated transcription factor, GLI2, was confined to the tumor-associated stroma.
Compared to adjacent nontumor liver, HCCs were also significantly enriched with GLI2(+)
stromal cells (Figure 1B). These findings suggest that malignant hepatocytes produce HH-
ligands that promote Hh signaling in adjacent stromal cells.
To assess glycolytic activity in these HCC we stained sections for pyruvate kinase M2
(PKM2), a rate limiting glycolytic enzyme and well-validated marker of glycolysis (15).
Unexpectedly, we found that PKM2 staining localized to HCC stroma, rather than to the
malignant hepatocytes themselves (Figure 1C). Dual staining for GLI2 and PKM2
confirmed that the Hh-responsive stromal cells were glycolytic and showed that HCC
stroma harbored greater numbers of glycolytic cells than adjacent nontumorous liver (Figure
1B, C). To further characterize these glycolytic stromal cells, we co-stained other sections
for PKM2 and alpha smooth muscle actin (ASMA), a MF marker (4). Expression of PKM2
co-localized with ASMA, demonstrating that the glycolytic tumor-associated stromal cells
were Hh-responsive MF (Figure 1D).
Hh inhibitor depletes glycolytic MF from tumor stroma in murine HCC model
Progressive liver injury and fibrosis occur in Mdr2−/− mice due to deficient transport of
phosphatidyl choline into bile. Primary hepatocellular carcinomas emerge spontaneously
between 50-60 weeks of age, modeling the natural evolution of HCC during fibrogenic
repair of various types of chronic liver injury (16). Therefore, we used
immunohistochemistry to characterize the tumor-associated stroma in HCC that were micro-
dissected from these mice. As noted in our human HCC cohort (Fig 1B-D), tumor-associated
stroma in the mouse model was enriched with cells that co-expressed ASMA and PKM2
(Fig 2A). Therefore, glycolytic MF localize within the HCC-associated stroma in both
species, and this seems to occur irrespective of the etiology of the underlying liver disease.
In human HCC, the glycolytic MF co-stained for GLI2 (Fig 1B) and thus, were presumed to
be Hh-responsive. To examine the role of Hh signaling in regulating glycolytic activity in
the murine tumor stromal cells, we compared expression of Glut1, a glucose transporter, and
several key glycolytic enzymes in mRNA isolated from HCCs of Mdr2-deficient mice that
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had been treated with either vehicle or the Smoothened antagonist, GDC0449, for 9 days
prior to sacrifice. Treatment with the Hh inhibitor reduced expression of mRNAs encoding
Gli2, Glut1, glycolytic enzymes, and αSma (Fig 2B). Immunohistochemistry confirmed that
reduced expression of MF- and glycolysis-associated mRNAs was paralleled by depletion of
tumor stromal cells that expressed ASMA, PKM2, and monocarboxylate transporter 4
(MCT4), a facilitator of lactate export (17) (Fig 2C).
Paracrine Hh signaling between hepatoma cells and MF stimulates glycolysis in MF
To determine if hepatoma cells generate soluble HH-ligands that might stimulate glycolytic
activity in Hedgehog-responsive MF, we compared Gli-luciferase reporter activity in Shh-
LightII cells that were exposed to conditioned medium from HepG2 cells, co-cultured with
HepG2 cells in a Transwell system, or treated with control medium without or with
recombinant SHH (Fig 3A). Like recombinant SHH, exposure to HepG2 cell-derived
soluble factors significantly increased Hh signaling in the Shh-LightII cells. The stimulatory
effect of HepG2 conditioned medium was abrogated by adding 5E1, a Hh neutralizing
antibody that blocks HH ligand-Ptc interaction (18) (Fig 3A). Moreover, when HepG2 cells
were replaced with cells that do not generate HH-ligands (Panc 10.05 cells) (19) and
experiments were repeated, no change in Shh-LightII cell luciferase activity was observed
(Supplemental Fig 1A). The aggregate data, therefore, indicate that HepG2 cells generate
soluble, biologically-active HH-ligands.
To determine if these HepG2-derived HH ligands functioned as inducers of MF glycolysis,
we cultured a well-characterized rat liver MF line (8B cells) (14) alone (monoculture) or in
the Transwell system with HepG2 cells, and assessed MF glycolytic activity. Co-culturing
MF with HepG2 cells induced MF expression of mRNAs that encode key glycolytic
enzymes (Fig 3B), and increased their lactate/pyruvate ratio, a measure of glycolytic activity
(Fig 3C). Treating MF with HepG2 cell-conditioned media had similar effects (Fig 3D). The
stimulatory effects of HepG2-conditioned medium on MF glycolysis were attenuated by
adding 5E1 to block HH ligand-Ptc interactions (Fig 3E), suggesting that HH-ligands are the
factors that malignant hepatocytes release to induce glycolytic activity in neighboring MF.
To verify that activating Hh signaling in MF promotes glycolysis, we treated monocultures
of liver MF with recombinant SHH (rSHH) ligand. Compared to vehicle-treated MF, MF
treated with rSHH ligand had increased expression of genes encoding glycolytic enzymes
(Fig 3F) and higher lactate/pyruvate ratios (Fig 3G). GDC-0449, a direct antagonist of the
Hh signaling intermediate, Smoothened, reversed the effects of rSHH-ligand, confirming
that MF glycolysis is regulated by canonical Hh signaling (Fig 3G). Treating MF with rSHH
also significantly increased their secretion of lactate into the media, while adding GDC-0449
reduced media lactate below basal levels, demonstrating that Hh signaling also regulates MF
secretion of lactate (Fig 3H). Finally, to determine if cancer cells that do not generate Hh
ligands can induce MF glycolysis, we compared expression of pkm2 and mct4 mRNAs in
MF that were exposed to soluble factors derived from Panc 10.05 cells (Supplemental Fig
1C, D). As predicted by the data shown in Supplemental Fig 1A, Panc 10.05 cells were
unable to induce MF expression of Ptc, a known Hh-target gene (Supplemental Fig 1B).
However, they did increase MF expression of both glycolysis markers, albeit at significantly
lower levels than were induced by HepG2 cells. Thus, while malignant hepatocytes release
Hh ligands to activate glycolysis in neighboring stromal cells, pancreatic cancer cells are
able to achieve this via other mechanisms that do not require Hh-Ptc paracrine interactions.
Lactate generated by glycolytic MF fuels lipogenesis in HepG2 cells
Never-the-less, our aforementioned findings identified a novel Hh-dependent mechanism
whereby malignant hepatocytes modulate the metabolic activity of tumor-associated MF.
Because tumor stroma is generally believed to support the growth of malignant epithelial
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cells, we used the Transwell co-culture system to evaluate the related hypothesis that MF-
derived glycolytic end-products (such as lactate) enhance net energy homeostasis of
malignant hepatocytes. Compared to mono-cultured HepG2 cells, HepG2 cells that were co-
cultured with liver MF demonstrated significant accumulation of Oil Red O-stained lipid
droplets (Fig 4A). Because lipid accumulation occurs during energy excess, we compared
the ATP content of mono- and co-cultured HepG2 cells and found significantly higher ATP
content in the co-cultured HepG2 cells (Fig 4B). Consistent with increased lipogenesis
during co-culture, co-cultured HepG2 cells expressed higher mRNA levels of the lipogenic
transcription factor, Pparγ, than mono-cultured HepG2 cells (Fig 4C). Co-culture also
enhanced HepG2 expression of monocarboxylate transporter 1 (Mct1), which encodes a
lactate transporter (17), but suppressed expression of pyruvate dehydrogenase kinase (Pdk1),
which encodes an enzyme that gates entry of pyruvate into the tricarboxcylic acid (TCA)
cycle (Supplemental Fig 3). These findings suggest that malignant hepatocytes import MF-
derived lactate and convert it into pyruvate to fuel ATP and lipid biosynthesis. To assess this
issue more directly, we treated monocultured HepG2 cells with lactate in the absence or
presence of FX11. FX11 inhibits the activity of lactate dehydrogenase, thereby blocking the
interconversion of lactate and pyruvate (20). Treating HepG2 cells with lactate significantly
increased lipid accumulation and ATP content. Both responses were prevented when cells
were pre-treated with FX11 to inhibit intracellular conversion of lactate into pyruvate (Fig
4D). Similar results were obtained when another hepatoma cell line, Huh7.5, was co-
cultured with liver MF or treated directly with lactate (Supplemental Fig 4), providing
reassurance that the findings were not restricted to a single liver cancer cell line.
The aggregate data, therefore, support a model whereby malignant hepatocytes generate
HH-ligands to orchestrate the construction of a Hh-responsive stroma that nurtures further
growth of the malignant epithelia. The cancer-associated process resembles epithelial-
stromal interactions that are triggered by injury to nonmalignant liver epithelial cells. When
damaged, such cells begin to produce HH-ligands that also act in a paracrine fashion to
promote accumulation of Hh-dependent MF (5). In nontumorous cirrhotic livers, MF are a
major source of fibrous matrix, but also produce various factors that promote the survival of
residual liver epithelial cells (4). Here we identify end-products of Hh-dependent changes in
MF metabolism as novel trophic factors for malignant hepatocytes by showing that Hh
signaling in MF stimulates glycolysis, and demonstrating that malignant hepatocytes use
MF-derived lactate to generate ATP and fuel lipogenesis (Supplemental Fig 5). Evidence
that the lactate-induced responses are blocked by treating malignant hepatocytes with an
inhibitor of lactate dehydrogenase suggests that the improved epithelial energy balance
occurs because malignant hepatocytes convert the assimilated lactate into pyruvate, which is
then shunted into the TCA cycle to increase mitochondrial ATP production. In HCCs,
therefore, increased aerobic glycolytic activity (i.e., the Warburg effect) is an end result of
collaborations between malignant hepatocytes and glycolytic MF in the tumor associated
stroma. Via this process, the malignant hepatocytes reap the benefits of the excess lactate
generated by glycolysis without becoming glycolytic themselves, thereby fully retaining the
capacity for oxidative phosphorylation and efficient ATP synthesis. Although this concept is
contrary to conventional dogma which localizes the Warburg effect to the malignant cells
themselves (15), it is consistent with other recent reports of lactate production by stroma in
breast cancer (21), and raises the intriguing possibility that Hh-mediated switches in stromal
cell metabolism also occur in cancers other than HCC. In any case, evidence for increased
glycolytic activity in tumor-associated MF has important diagnostic and therapeutic
implications. It suggests that positron emission tomography (PET) scans might be deployed
to identify HCC that are particularly enriched with glycolytic stroma. The latter information
might facilitate HCC detection, and could also have prognostic significance because highly
glycolytic tumors tend to have more aggressive biology (22). Knowing which HCC are most
enriched with glycolytic stroma would also justify, and help to refine, novel treatment
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approaches for HCC, supporting consideration of Hh inhibitors, LDH antagonists, and
glycolysis inhibitors, as potential therapies for some patients with this life-threatening
disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Evidence for paracrine Hedgehog signaling between malignant epithelia and tumor
stroma in human HCC
Tumor and adjacent nontumorous liver from 5 patients with HCC were evaluated by
immunohistochemistry (IHC) and quantitative morphometry. Representative sections are
shown and morphometric (mean +/− SEM) or cell count (mean +/− SD) data are graphed;
*p<0.05 for tumor vs nontumorous tissue. (A) SHH ligand (brown, 50x). Dotted lines
enclose fibrotic capsule. (B) GLI2 (arrows, 400x) (C) PKM2 (brown) in non-tumor and
tumor nodules (400x). (D) Co-localization of PKM2 (green) with αSMA (brown) in tumor
nodule (400x, 1000x insert).
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Figure 2. Murine HCC stroma is enriched with Hh-dependent glycolytic MF
Mdr2-deficient mice with HCC were treated with the Hh-inhibitor, GDC-0449, or vehicle
(N=5 mice/group); effects on stroma of microdissected tumor nodules were evaluated by
morphometry of immunostained sections and QRT-PCR. Representative sections and mean
+/− SEM data are displayed (*p<0.05, **p<0.01 GDC-0449-vs. vehicle-treated groups). (A)
Co-localization of PKM2 (green) with αSMA (brown) in tumor from vehicle-treated mouse
(400x). (B) QRT-PCR for Gli2, αSma, Glut1, Hk2, Pgk1 in liver tumor mRNA. (C) Tumor
sections from Vehicle- and GDC-0449 treated mice demonstrate (Top) αSMA, (Middle)
PKM2, and (Bottom) MCT4 (brown, 200x)
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Figure 3. Paracrine Hh signaling stimulates MF glycolysis
(A) Gli-luciferase reporter activity in Shh-LightII cells incubated with control medium,
1000ng/mL recombinant SHH ligand, co-cultured with HepG2 in a Transwell system,
incubated with HepG2-conditioned media without or with 5E1 neutralizing antibody;
(*p<0.05, **p<0.01). (B) Pkm2 and Mct4 mRNA levels in MFs grown in monoculture or
co-cultured with HepG2s in Transwells. (C) Intracellular (I.C.) lactate/pyruvate ratio in MFs
mono-cultured or co-cultured with HepG2 cells. (D) Pkm2, Mct4, and Patched mRNA levels
in MFs grown in control-media or with HepG2-conditioned media (CM). (E) Pkm2, Mct4,
and Patched mRNA levels in MFs grown in HepG2-conditioned media (CM) without or
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with 5E1 neutralizing antibody (F) Pkm2 and Mct4 mRNA levels in MFs treated with
Vehicle or recombinant SHH ligand (rSHH-L). (G) Intracellular (I.C.) lactate/pyruvate ratio
in MFs after treatment with rSHH-L. (H) Lactate exported into media by MFs treated with
control media, rSHH-L or rSHH-L+GDC-0449. Mean +/− SEM data from triplicate
experiments are graphed; *p<0.05, **p<0.01 vs. respective controls.
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Figure 4. Lactate generated by glycolytic MF fuels lipogenesis in HepG2 cells
(A) Oil Red O staining of HepG2 cells grown alone or co-cultured in Transwells with MFs
and quantified by morphometry. (B) Intracellular ATP and (C) MCT1, PPARγ, PDK1
mRNA levels in HepG2 cells cultured alone or in Transwells with MFs. (D) Change in Oil
Red O staining and ATP in HepG2s after treatment with 40mM lactate or FX11. Mean +/−
SEM data from triplicate experiments are graphed; *p<0.05, **p<0.01 vs. respective control
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